KISQALI 200 mg, film-coated tablet 63 tablets, CIP 3400930109359
Active ingredients: Ribociclib, Ribociclib succinate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet63 tablets, CIP 3400930109359orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- KISQALI 200 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) polychlortrifluoroéthylène PVC de 63 comprimé(s)
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 18 May 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68343525CIP73010935CIP133400930109359Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RIBOCICLIBcomprimé | 200 mg · un comprimé | FT |
| SUCCINATE DE RIBOCICLIBcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
- 21 tablets, CIP 3400930323434Commercialized according to BDPM
- 42 tablets, CIP 3400930323441Commercialized according to BDPM
- 63 tablets, CIP 3400930323458Commercialized according to BDPM
- 21 tablets, CIP 3400930109335Commercialized according to BDPM
- 42 tablets, CIP 3400930109342Commercialized according to BDPM
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.